Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRDME trial of bevacizumab versus ranibizumab for diabetic macular edema
NL-OMON27161Not yet recruiting
- Sponsor
- ZonMw
- Start
- Apr 2012
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in diabetic macular edema (DME) comparing Bevacizumab with Ranibizumab (2 arms). Primary endpoint: Change in best-corrected visual acuity. Planned start Apr 2012; status: not yet recruiting.
02
Drugs
bevacizumabranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON27161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27161.